{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-24-000001","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.764365+00:00","generated_at":"2026-06-07T03:06:58.620370+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Aurinia preliminary Q4 net product revenue $42M (+49% YoY); FY23 $159M; guides FY24 $200-220M","bullets":["Preliminary net product revenue Q4 2023: ~$42M, up 49% YoY from $28.3M; full-year ~$159M, up 53% from $103.5M.","Total revenue Q4: ~$45M (+59% YoY); full-year ~$176M (+31% YoY); cash & investments ~$351M at year-end.","Guides 2024 net product revenue $200-220M; targets cash flow positive in H2 2024.","Patients on LUPKYNIS therapy: ~2,066 at Dec 31, 2023, up from 1,525 a year earlier; 438 PSFs added in Q4.","Strategic review process ongoing; no further updates on potential sale or merger at this time."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-24-000001","json":"https://secwatch.observer/filing/0001600620-24-000001.json","markdown":"https://secwatch.observer/filing/0001600620-24-000001.md","text":"https://secwatch.observer/filing/0001600620-24-000001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000001/0001600620-24-000001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000001/auph-20240105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:06:58.620370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5351ae278245a4e01b1b200b74d0163276dbea9a","claim":"Aurinia Pharmaceuticals Inc. reported fourth quarter and full-year 2023 results: revenue approximately $45 million and $176 million. Guidance initiated.","evidence_excerpt":"AURINIA PROVIDES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL-YEAR 2023 NET REVENUE RESULTS Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000001/0001600620-24-000001-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year 2023"},{"label":"Revenue","value":"approximately $45 million and $176 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}